« Return to News | R&D Trends

Foundation Medicine, Johnson & Johnson collaborate in oncology research

Tuesday, October 25, 2011 01:10 PM

Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine's comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.

This collaboration marks Foundation Medicine's fourth pharmaceutical company alliance this year, following collaborations with Novartis and Celgene, and one undisclosed alliance.

"We are very pleased to work with J&JPRD and for our test to be used in the ongoing clinical development of new targeted cancer therapies," said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. "Cancer care is being improved by new therapies that target the molecular drivers of individual tumors. Our test may help identify patients that are more likely to respond to targeted therapies, which could accelerate clinical development and give physicians additional ways to effectively treat patients. This collaboration is further validation of Foundation Medicine's approach and the value our comprehensive cancer genomic test can bring to pharmaceutical clinical trials."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.